United Kingdom (UK)
Recombinant monoclonal antibody to HIV GP41. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the llama peripheral lymphocytes 2E7 (L92E7).
UniProt Accession Number of Target Protein: P04578
Alternative Name(s) of Target: Glycoprotein 41; GP 41; TM; transmembrane protein 41; envelope glycoprotein gp160; env protein
Immunogen: The original antibody was generated by immunizing Llama galama with two different types of antigens gp140 CN54 (subtype B′/C) and gp140 UG37 (subtype A).
Specificity: This antibody binds a new linear epitope in the first heptad repeat of gp41 that is only exposed in the fusion-intermediate conformation.
Application Notes: This highly potent broadly neutralizing antibody binds HIV-gp41 and is capable of neutralizing HIV strains belonging to the A, A/G, B, B/C and C subtypes. The binding of the antibody to various envelope glycoprotein was confirmed using ELISA (PMID: 22438910). A bispecific VHH with 2E7 and CD4bs VHH (J3/3E3) was reported to enhance strain specific potencies up to 1400 folds higher than the mixture of the individual VHHs (PMID: 31544844).
Antibody first published in:
Strokappe et al. Llama antibody fragments recognizing various epitopes of the cd4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS One. (2012); 7(3): e33298. PMID:22438910
Note on publication:
Describes the generation and neutralizing properties of this antibody.